- Home
- CRIS vs BCAB Comparison
CRIS vs BCAB Comparison
Compare CRIS & BCAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CRIS | BCAB |
|---|---|---|
| Founded | 2000 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.0M | 12.5M |
| IPO Year | 2000 | 2020 |
Fundamental Metrics
Financial Performance| Metric | CRIS | BCAB |
|---|---|---|
| Price | $0.97 | $0.17 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 2 | 3 |
| Target Price | ★ $16.50 | $1.00 |
| AVG Volume (30 Days) | 108.0K | ★ 1.5M |
| Earning Date | 01-01-0001 | 06-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 23.21 | ★ 44.19 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $9,898,000.00 | $300,000.00 |
| Revenue This Year | $6.13 | N/A |
| Revenue Next Year | $7.86 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 31.50 | N/A |
| 52 Week Low | $0.77 | $0.13 |
| 52 Week High | $3.13 | $1.43 |
Technical Indicators
Market Signals| Indicator | CRIS | BCAB |
|---|---|---|
| Relative Strength Index (RSI) | 41.08 | 38.09 |
| Support Level | $0.95 | $0.14 |
| Resistance Level | $1.04 | $0.27 |
| Average True Range (ATR) | 0.07 | 0.02 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 12.75 | 11.00 |
Price Performance
Historical ComparisonAbout CRIS Curis Inc.
Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.